Idexx Laboratories, Inc. [IDXX] stock is trading at $477.84, up 0.36%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IDXX shares have gain 1.52% over the last week, with a monthly amount glided 0.13%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Idexx Laboratories, Inc. [NASDAQ: IDXX] stock has seen the most recent analyst activity on July 25, 2024, when BTIG Research initiated its Buy rating and assigned the stock a price target of $580. Previously, Piper Sandler downgraded its rating to Neutral on January 30, 2024, and kept the price target unchanged to $525. On December 07, 2023, Exane BNP Paribas initiated with a Outperform rating and assigned a price target of $602 on the stock. Cleveland Research upgraded its rating to a Buy. Atlantic Equities downgraded its rating to a Neutral but $610 remained the price target by the analyst firm on August 02, 2023. Stifel downgraded its rating to Hold for this stock on July 25, 2022, but kept the price target unchanged to $415. In a note dated July 21, 2022, Goldman upgraded an Buy rating on this stock and revised its target price from $530 to $435.
Idexx Laboratories, Inc. [IDXX] stock has fluctuated between $372.50 and $583.39 over the past year. Currently, Wall Street analysts expect the stock to reach $479.75 within the next 12 months. Idexx Laboratories, Inc. [NASDAQ: IDXX] shares were valued at $477.84 at the most recent close of the market. An investor can expect a potential return of 0.4% based on the average IDXX price forecast.
Analyzing the IDXX fundamentals
Idexx Laboratories, Inc. [NASDAQ:IDXX] reported sales of 3.72B for the trailing twelve months, which represents a growth of 7.10%. Gross Profit Margin for this corporation currently stands at 0.6% with Operating Profit Margin at 0.3%, Pretax Profit Margin comes in at 0.29%, and Net Profit Margin reading is 0.23%. To continue investigating profitability, this company’s Return on Assets is posted at 0.26, Equity is 0.64 and Total Capital is 0.47. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.68.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 472.02 points at the first support level, and at 466.19 for the second support level. However, for the 1st resistance point, the stock is sitting at 485.57, and for the 2nd resistance point, it is at 493.30.
Ratios To Look Out For
For context, Idexx Laboratories, Inc.’s Current Ratio is 1.51. As well, the Quick Ratio is 1.10, while the Cash Ratio is 0.42. Considering the valuation of this stock, the price to sales ratio is 10.60, the price to book ratio is 25.24 and price to earnings (TTM) ratio is 46.30.
Transactions by insiders
Recent insider trading involved Claflin Bruce L., Director, that happened on May 17 ’24 when 200.0 shares were sold. Executive Vice President, POLEWACZYK JAMES F completed a deal on Mar 06 ’24 to sell 8104.0 shares. Meanwhile, Director Vandebroek Sophie V. sold 1404.0 shares on Mar 05 ’24.
